Phagenesis Ltd
Klaus Annewanter has a diverse work experience spanning over several industries. Klaus began their career as an ICU Nurse at BKH Kufstein and Donauspital Vienna, where they worked from October 2002 to January 2006. Klaus then joined Medtronic in February 2006, initially as a Technical Consultant in Cardiac Rhythm Disease Management before being promoted to Senior Technical Consultant in September 2009. Klaus transitioned into the role of Sales Representative in Neuromodulation in November 2010 and later became a Sales Coordinator in Gastro/Uro in May 2014. In August 2015, Klaus joined Phagenesis Ltd as a Therapy Development Manager, where they are responsible for therapy, market, and business development, as well as reimbursement, clinical trials, sales, and marketing.
Klaus Annewanter's education history includes attending BKH Kufstein, where they obtained a Diplom Gesundheits-und Krankenpflege degree in an unspecified field of study. Klaus also attended BRG Kufstein, where they earned their Matura degree in an unspecified field of study as well. No specific start or end years are provided for both educational experiences.
This person is not in any offices
Phagenesis Ltd
1 followers
Phagenesis is developing a device for the treatment for dysphagia, the inability to swallow safely, that often accompanies stroke or other neuro-deficit diseases. The approach is to harness the brain's own capacity for relearning functions that have been lost through brain damage (via "neuroplasticity" or "corticalremapping"). Focusing initially on the care of stroke patients as they recover in hospital (acute care), Prof Shaheen Hamdy of the University of Manchester, UK, painstakingly devised a method of delivering electrical signals from the pharynx (throat) along nerve cells directly to the relevant parts of the brain. The results of his work have been published in top peer-reviewed scientific and medical journals, including The Lancet, the Nature group of publications, and Gastroenterology.